Third Harmonic Bio
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2019-01-01
- Employees
- 30
- Market Cap
- $507.5M
- Website
- http://thirdharmonicbio.com
- Introduction
Third Harmonic Bio, Inc. develops pharmaceutical products for the treatment of allergic and immune diseases and disorders. It focuses on the development of the next wave of medicine for the treatment of allergic and inflammatory diseases. The company was founded on April 25, 2019 and is headquartered in San Francisco, CA.
Clinical Trials
8
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
A First in Human Trial Evaluating THB335 in Healthy Participants
- Conditions
- Healthy
- Interventions
- Drug: THB335 single doseDrug: THB335 fasted/fedDrug: THB335 multiple doseDrug: Single dose placeboDrug: Placebo fasted/fedDrug: Multiple dose placebo
- First Posted Date
- 2024-05-22
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Third Harmonic Bio, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT06425861
- Locations
- 🇺🇸
QPS Miami, Miami, Florida, United States
A Study to Evaluate THB001 in Adult Patients With Chronic Cold Urticaria
- First Posted Date
- 2022-08-22
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Third Harmonic Bio, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT05510843
- Locations
- 🇩🇪
Charité - Universitätsmedizin Berlin Institute of Allergology, Berlin, Germany
🇳🇱Centre for Human Drug Research, Leiden, Netherlands
News
Tang Capital's Concentra Biosciences Acquires Elevation Oncology for $0.36 Per Share in Latest Biotech Liquidation
Elevation Oncology has agreed to be acquired by Concentra Biosciences, controlled by hedge fund Tang Capital Partners, for $0.36 per share in cash with additional contingent value rights.
Biotech Funding Plummets 57% to $2.7 Billion as Trump Administration Policies Shake Investor Confidence
Biotech funding dropped 57% to $2.7 billion in May 2025, marking one of the worst funding periods in three years according to Jefferies investment bank analysis.
Third Harmonic Bio Stockholders Approve Liquidation Plan as THB335 Shows 85% Tryptase Reduction in Phase 1 Trial
Third Harmonic Bio stockholders overwhelmingly approved a liquidation and dissolution plan with 99.9% of voting shares supporting the proposal at the June 5, 2025 annual meeting.
Third Harmonic Bio's THB335 Shows Promising Phase 1 Results for Chronic Urticaria Treatment
Third Harmonic Bio's Phase 1 trial of THB335, a selective KIT inhibitor, demonstrated favorable safety profile and pharmacokinetics supporting once-daily dosing in healthy volunteers.
Blueprint Medicines' BLU-808 Shows Superior Profile Over Third Harmonic's THB001 in KIT Inhibitor Race
Blueprint Medicines reports promising Phase 1 data for BLU-808, demonstrating favorable pharmacokinetics supporting once-daily dosing in healthy volunteers.
Third Harmonic Bio Appoints Geoff McDonough to Board of Directors, Advancing THB335 for Chronic Spontaneous Urticaria
Third Harmonic Bio appointed Geoff McDonough, M.D., to its Board of Directors, enhancing its leadership with extensive clinical and commercial experience.